Xenon Pharmaceuticals announced Phase 3 X‑Tole2 results for azetukalner showing a 53.2% placebo‑adjusted reduction in focal onset seizure frequency at the 25 mg dose and strong tolerability at the lower dose. The company said the readout exceeded expectations and plans an FDA filing in the third quarter. Xenon highlighted the pill’s once‑daily oral dosing and a safety profile that analysts called competitive versus current antiepileptic drugs. The CEO framed the result as a transformational efficacy signal, and the market reacted with a large intraday stock rally. Company filings will now be prepared toward an NDA submission timeline driven by the robust efficacy signal and manufacturing readiness. If approved, azetukalner could add a new mechanism (KV7 potassium channel modulation) to the epilepsy toolkit, affecting both clinical positioning and commercial dynamics in antiepileptic drug development.